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The glucagon-like peptide-1 (GLP-1) receptor is one of the best validated therapeutic targets for the treatment of type 2 diabetes
mellitus (T2DM). Over several years, the accumulation of basic, translational, and clinical research helped deﬁne the physiologic
roles of GLP-1 and its receptor in regulating glucose homeostasis and energy metabolism. These eﬀorts provided much of the
foundation for pharmaceutical development of the GLP-1 receptor peptide agonists, exenatide and liraglutide, as novel medicines
for patients suﬀering from T2DM. Now, much attention is focused on better understanding the molecular mechanisms involved
in ligand induced signaling of the GLP-1 receptor. For example, advancements in biophysical and structural biology techniques
are being applied in attempts to more precisely determine ligand binding and receptor occupancy characteristics at the atomic
level. These eﬀorts should better inform three-dimensional modeling of the GLP-1 receptor that will help inspire more rational
approaches to identify and optimize small molecule agonists or allosteric modulators targeting the GLP-1 receptor. This article
reviewsGLP-1 receptorphysiologywithanemphasisonGLP-1induced signalingmechanismsinordertohighlight newmolecular
strategiesthathelpdeterminedesiredpharmacologiccharacteristicsforguidingdevelopmentoffuturenonpeptideGLP-1receptor
activators.
1.Introduction
T h eg l u c o r e g u l a t o r yr o l eo ft h eg u ti sd e m o n s t r a t e db y
studies showing insulin secretion is profoundly more robust
following glucose ingestion compared to the insulinotropic
response achieved by parenteral administration of intra-
venously infused glucose [1–5]. This physiologic phe-
nomenon, coined the “incretin eﬀect,” is primarily mediated
by two enteric factors known as the incretins: glucagon-
like peptide-1 (7-37)/(7-36)-amide (GLP-1) and glucose
dependent insulinotropic polypeptide (1-42) (GIP) [6–13].
In addition to glucose, the presence of other macronutrients
in a mixed meal, such as lipids and amino acids, in the
intestinal lumen stimulate a similar incretin response [14,
15]. When moving through the intestine, nutrients interact
directlywith sensory receptors andintegral membrane chan-
nel and transporter proteins localized on the microvillus-
rich apical membrane surface of open-type endocrine cells.
These cells are embedded in the mucosal lining throughout
variousregionsoftheintestinaltractandreleasetheincretins
uponnutrientstimulation.InL-cells,locatedthroughoutthe
intestine but predominantly found in the ileum of the distal
small intestine and colon [16, 17], GLP-1 is produced by
posttranslational cleavage of the 160-amino acid proglucaon
precursor protein [18, 19], a process requiring prohormone
convertase-1/3 [20–22]. GIP is the single peptide derived
from proteolytic processing of a 153-amino acid precursor
protein [23] expressed in endocrine K-cells located mainly
in the duodenum and proximal jejunum of the upper small
intestine [24].
1.1. Physiologic Action of GLP-1. Upon release into the circu-
lation, GLP-1 and GIP facilitate glucose disposal by directly
acting on pancreatic islets to enhance postprandial insulin
secretion [6–13]. This process is mediated by two class
B1 (secretin-like family) seven transmembrane spanning,2 Experimental Diabetes Research
heterotrimeric G-protein coupled receptors (GPCRs) that
signal in response to binding and occupancy by GLP-1
[25, 26]a n dG I P[ 27], respectively. Both of these GPCRs
predominantly couple to the Gαs subunit which activates
adenylyl cyclases to increase intracellular cyclic 3 5 AMP
(cAMP). Genetic deletion of both receptors in mice leads
to glucose intolerance and defects in glucose stimulated
insulinsecretion[28].InadditiontoligandstimulatedcAMP
generation, β-arrestin interaction [29, 30] and signaling
pathways that mobilize intracellular calcium are important
eﬀectors of incretin action [31, 32].
In humans, the incretin eﬀect is often reduced in pa-
tients suﬀering from type 2 diabetes mellitus (T2DM)
[33]. To combat this, initial strategies to develop incretin
based “replacement” therapies largely focused on GLP-1
receptor analogs because studies suggested diabetic patients
are resistant to GIP treatment [34, 35], while GLP-1 infusion
elicits a strong insulin secretory response and can normalize
hyperglycemia [36–39]. In contrast to GIP, GLP-1 also
induces several additional antidiabetic eﬀects, including in-
hibition of glucagon secretion [6, 8] and gastric emptying
[40–42] (which both help improve postprandial glucose
control) and a decrease in appetite and food intake [43–47].
These latter eﬀects are mediated by the GLP-1 receptor ex-
pressed in extrapancreatic tissues, most notably those of the
gastrointestinal tract and central nervous system.
Whileinfusionregimensdemonstrateremarkableantidi-
abetic pharmacology, elimination metabolism and phar-
macokinetic characteristics of native GLP-1 present major
hurdles to developing it as an eﬀective pharmaceutical agent.
One signiﬁcant challenge in pursing GLP-1 based molecules
is that GLP-1 is rapidly inactivated by dipeptidyl peptidase
4 (DPP4), a plasma membrane bound enzyme that is posi-
tioned with its active site orientated towards the extracellular
space. This ubiquitously expressed “ectopeptidase” cleaves
the N-terminal dipeptide, His7-Ala8, to inactivate GLP-1
[48, 49]. Removal of these residues dramatically reduces
the binding aﬃnity of the peptide for the GLP-1 receptor,
thus abolishing its ability to eﬀectively activate receptor sig-
naling [50]. DPP4 is highly expressed on the surface of
endothelial cells lining blood vessels; consequently, GLP-1
is immediately vulnerable to inactivation following release
into the circulation [51]. Upon cleavage, the inactive GLP-1
metabolite is eliminated by the kidney [52]. As a result of
rapid postsecretory proteolysis and renal elimination, the
biological half-life of GLP-1 is estimated to be between 1 to
2m i n u t e s[ 53, 54]. These characteristics limit the pharma-
ceutical potential of native GLP-1.
1.2. GLP-1 Receptor Peptide Agonists. Several eﬀorts pursued
novel GLP-1 analogs with improved metabolic properties.
A common approach was to introduce N-terminally substi-
tuted modiﬁcations to reduce DPP4 sensitivity [54–56]. To
date, attempts solely focused on amino acid substitutions of
native GLP-1 to identify longer acting molecules likely have
been hampered by other issues such as renal clearance and
secondary degradation by other endopeptidases. However,
two alternate approaches proved successful in advancing
more stable, degradation resistant GLP-1 receptor agonists.
Both exenatide and liraglutide are approved for marketing
by several government regulatory agencies for the treatment
of T2DM.
Exenatide is a 39-amino acid peptide GLP-1 receptor
agonist that is fully eﬃcacious in cellular assays and compe-
titive with native GLP-1 in receptor binding studies [26, 57–
59]. It is the synthetic version of exendin-4 which was
among several bioactive peptides containing an N-terminal
histidine identiﬁed in crude venom preparations extracted
from perimandibular salivary glands of Helodermatidae
lizards [60, 61]. Exendin-4 was isolated from the poisonous
venom of the Gila monster, Heloderma suspectum [60], a
lizard indigenous to the southwest United States in the Gila
River area of New Mexico and Arizona [62]. In addition to
mimicking the physiologic glucoregulatory actions of native
GLP-1, exendin-4 is a poor DPP4 substrate [63] and is
cleared from the body primarily by glomerular ﬁltration in
the kidney [64, 65]. Consequently, exenatide has a longer
duration of action compared to GLP-1 [66–68]a n da ne s t i -
mated biological half-life of approximately 4 hours [64, 69].
In April of 2005, under the brand name Byetta,e x e n a t i d e
becametheﬁrstenteroendocrinebasedtherapeuticapproved
by the United States Food and Drug Administration (FDA)
for the treatment of T2DM.
The second GLP-1 receptor agonist approved to treat
T2DM is liraglutide (NN2211). For this molecule, a “fatty
acid derivatization” strategy was used to prolong the in vivo
actionofGLP-1.Thisapproachattachesafattyacidmoietyto
GLP-1inordertofacilitateGLP-1bindingtoserumalbumin.
L i r a g l u t i d ei sa c y l a t e do nL y s 26 with a covalently attached
palmitoyl (C16:0) chain [70]. As this modiﬁcation enables
binding to albumin, GLP-1 is then sterically protected from
DPP4 degradation [70]. The plasma half-life of liraglutide is
e s t i m a t e dt ob eb e t w e e n1 1a n d1 5h o u r s[ 71, 72]. Under the
brand name Victoza, liraglutide received marketing approval
by the FDA in January of 2010 for the treatment of T2DM.
ByettaandVictoza arebothcommonlyprescribedmedicines.
2.GLP-1Receptor SignalTransduction
andSecond Messenger Pathways
As the best characterized in vivo action of GLP-1 is an
acute insulinotropic eﬀect mediated by the GLP-1 receptor
in pancreatic β-cells, the signal transduction coupling mech-
anismsofthisreceptorprimarilyhavebeenanalyzedusing ex
vivopreparationsofpancreaticislets,transformedpancreatic
β-cell lines, and recombinant GLP-1 receptor expressing
systems, Accordingly, critical evaluation of GLP-1 receptor
signal transduction in extrapancreatic tissues can be made
by inference only. Use of the various peptide GLP-1 receptor
agoniststodeﬁnetheinvitropharmacologicpropertiesofthe
receptorshoulddeﬁnekeyassaysystemstoenableoptimizing
small molecule GLP-1 receptor activators.
2.1. GLP-1 Receptor Activation. Both GLP-1 and exendin-4
are α-helical peptides that interact with the GLP-1 receptor
by binding multiple extracellular contact points to induceExperimental Diabetes Research 3
receptor signaling [73–75]. Similar to the “two-step” mecha-
nism proposed for other class B1 GPCRs [76]( Figure 1), the
GLP-1 receptor utilizes an N-terminal extracellular domain
as an “aﬃnity trap” to recognize and bind peptide ligands
[77, 78]. The N-terminal domain of the GLP-1 receptor is
conservedamongclassB1GPCRsforminganα-β-βαprotein
fold that has structural homology to the sushi/CCP/SCR
protein folds [79, 80]( Figure 2). This structure, referred to
as an “ectodomain” (ECD), is a trilayer fold composed of
an N-terminal α-helix, a middle section of two antiparallel
β strands, and a ﬁnal lobe composed of two additional
antiparallel β sheets and a short α-helical region (βα)
(Figure 2). The overall structure of the ECD is stabilized by
three pairs of disulﬁde bonds formed between six conserved
cysteine residues that lock the three layers of the ECD
together [81]( Figure 2). X-ray crystal structures of exendin-
4 and GLP-1 bound to the ECD conﬁrm the “aﬃnity
trap” hypothesis showing the C-terminal α-helical region of
GLP-1 or exendin-4 is positioned within a binding cleft of
the N-terminal ECD [74, 75]( Figure 3). Both GLP-1 and
exendin-4 are amphipathic in nature, and this deﬁnes their
structurally conserved interaction mechanism with the ECD.
The hydrophobic faces of GLP-1 and exendin-4 make the
majority of interactions with the ECD and likely are the
key contributors to ECD/ligand aﬃnity with only a minor
contribution of binding energy provided by the hydrophilic
regions of GLP-1 receptor agonist peptides [74, 75]
(Figure 3).
The second step of the class B1 GPCR activation model
predicts the ECD docks the bound peptide in a position that
promotes direct contact of N-terminal residues of the ligand
with the central activation pocket of the receptor, a region
consisting of three interconnecting extracellular loops often
referred to as the helical bundle or “J” (juxtamembrane)
domain. GLP-1 (or exendin-4) binding to this core region
induces a conformational rearrangement of the membrane-
spanning α-helices, eliciting a shift of the intracellular
receptor loops to stimulate intracellular signal transduction
(Figure 1).
StructuralinformationregardingGLP-1receptorpeptide
ligands is available primarily from NMR studies. The data
are consistent with other class B1 GPCR ligands [83] in that
GLP-1(7-36) and exendin-4 peptides are likely α-helical in
structure with disordered N-termini, although the artiﬁcial
environment in which these studies are conducted must be
used to qualify any interpretation of the experimental data
[84,85].StructuralstudiesofclassB1GPCRECDshavebeen
very informative regarding the molecular mechanisms of
peptideligandselectivityandhavegeneratednewhypotheses
regarding class B1 GPCR activation mechanisms. However,
the ﬁeld awaits deﬁnitive structural data to explain how
peptide agonists activate their cognate class B1 GPCRs.
2.2. G-Protein Coupling. The GLP-1 receptor primarily cou-
ples to the Gαs heterotrimeric G-protein. Upon ligand bind-
ing, the resulting conformational change activates intrinsic
guaninenucleotideexchangefactoractivityofthereceptorto
catalyze release of bound GDP from the Gαs. The Gαs then
rapidly binds GTP which leads to dissociation of Gαs and
Gβγ, consequently activating downstream eﬀector pathways.
Activated Gαs allosterically stimulates membrane-associated
adenylyl cyclases to catalyze conversion of ATP to cAMP,
which acts as an intracellular second messenger mediating
GLP-1 signaling.
Elevation of cAMP in the pancreatic β-cell is a critical
event in the process of glucose dependent insulin secretion
and is likely the key mechanism by which GLP-1 and
exendin-4 act on β-cells to potentiate insulin secretion [25,
26, 86]. However, early reports highlighted the ability of the
GLP-1 receptor to couple to alternative signaling pathways,
including phospholipase C (PLC) and the mobilization of
intracellular Ca2+ [87, 88], consistent with the known eﬀects
of GLP-1 to stimulate Ca2+ mobilization in β-cells [89].
Further, multiple reports indicate GLP-1 receptor couples to
Ca2+ mobilization when heterologously expressed [90, 91].
In these systems, it is generally assumed Ca2+ mobilization is
aG αq mediated process. In support of this, studies utilizing
the azidoanilide-GTP cross-linking method show the GLP-1
receptor can cause activation of the Gαq-a n dG αi-families
of G-proteins in GLP-1 receptor expressing CHO cells [88].
Conversely, recent experiments using membrane GTPγS
binding assays demonstrate GLP-1 receptor activation does
not induce measurable activation of Gαq or Gαi despite the
presence of substantial PLC independent Ca2+ mobilization
in GLP-1 receptor expressing HEK cells [91]. In vivo,p a n -
creatic β-cell speciﬁc dual inactivation of Gαq and Gα11 does
not aﬀect GLP-1 potentiation of glucose stimulated insulin
secretion[92],whereasinsulinotropicactionthroughknown
Gαq/11 coupled GPCRs, GPR40 and the M3 muscarinic
receptor, is ablated. While this study elegantly demonstrates
that Gαq/11 signal transduction is not required for GLP-1
receptor mediated insulin secretion (using perifused islets),
it is problematic that a single dose of 100μMG L P - 1( a
concentration greater than 5 orders of magnitude above the
Kd and peak circulating levels of active GLP-1) was used in
the studies [49, 92].
While a role for Gαq/11 signal transduction in β-cell
GLP-1 receptor action is generally excluded, a PLC and
Ca2+ mobilization pathway may be operant. Experiments
using mouse β-cells indicate the elevation of cAMP by
GLP-1 receptor signaling results in activated EPAC2 that
stimulates PLC [31]a n dC a 2+ channel recruitment [93]
to facilitate calcium induced calcium release, a process
integral for robust insulin secretion. These data provide a
potential mechanism whereby sole activation of the Gαs
pathway induces cAMP- and PLC/Ca2+ dependent responses
in β-cells. In light of the contrasting data, it is apparent
that the phenotype of GLP-1 receptor signaling may diﬀer
according to the cellular context in which the receptor is
expressed, a phenomenon now widely recognized but not
well understood within the GPCR ﬁeld [94]. Accordingly,
the deﬁnitive in vivo G-protein coupling proﬁle of the
GLP-1 receptor is unclear, although Gαs induced cAMP
accumulation is certainly integral to the biological response
of GLP-1 receptor activation. It is of interest that other class
B1 GPCRs demonstrate physiologically relevant coupling to
multiple G-proteins; the parathyroid hormone receptor is4 Experimental Diabetes Research
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Figure 1: The activation mechanism of the GLP-1 receptor. Biochemical and structural studies have led to a model of class B1 GPCR
activation by peptide hormones referred to as the “two-step” mechanism [82]. (a) In the unliganded state, the GLP-1 receptor (GLP-1R)
is in a predominately inactive conformation. The natural ligand GLP-1(7-36)-NH2 is freely diﬀusible in solution and likely has substantial
intrinsic α-helical structure. (b) An initial binding event between the globular ectodomain at the N-terminal of the GLP-1R and the C-
terminal of the GLP-1(7-36)-NH2 peptide occurs. This “low aﬃnity” interaction acts as a tether or “aﬃnity trap” to localize GLP-1 at the
GLP-1R. (c) The weak aﬃnity of the N-terminus of GLP-1(7-36)-NH2 is then able to productively engage with transmembrane domain
and loop residues of the receptor to induce a high aﬃnity interaction and likely a conformational change in the GLP-1R. (d) Coincident
with agonist binding, the G-protein bound conformation of the GLP-1R is stabilized. This represents the classic high aﬃnity agonist bound
state. (e) The high aﬃnity agonist bound state is transient in an intact system as the GLP-1R stimulates guanine nucleotide exchange on the
α-subunit of the G-protein heterotrimer, leading to G-protein dissociation and independent or synergistic activation of eﬀector proteins by
liberated Gα·GTP and Gβγ.
Figure 2: Structure of the GLP-1 receptor ectodomain. The overall
structure of the GLP-1 receptor ectodomain is depicted (PDB ID:
3IOL)[74].Thetripartiteα-β-βαstructureisannotatedusingcolor;
fromN-terminaltoC-terminalα(blue),β (green),βα(yellow).The
three conserved disulﬁde bonds that stabilize the tertiary structure
of the ectodomain are colored in red.
the best characterized example [95]. The use of genetically
modiﬁed mice, RNA interference, or novel pharmacological
tools such as the Gαq/11 inhibitor YM-254890 [96] may serve
to answer whether the GLP-1 receptor functionally couples
to G-proteins other than Gαs in the endogenous context,
particularly in extrapancreatic cell types.
2.3. β-Arrestin Coupling. Despite numerous studies charac-
terizing β-arrestin interactions with GPCRs, only a limited
number of reports investigate interactions between incretin
receptors and arrestin proteins. Bioluminescence reso-
nance energy transfer studies demonstrate both β-arrestin-1
Figure 3: Structural determinants of ligand binding to the GLP-
1 receptor ectodomain. (a) Structure of the GLP-1 receptor
ectodomain bound to GLP-1. Blue ribbon and space ﬁlling model is
GLP-1 receptor and the red ribbon and stick model is GLP-1. Data
are derived from PDB ID: 3OL.
and -2 interact with the GLP-1 receptor in an agonist
dependent manner [97]. Classically, GPCR recruitment of
GPCR kinases (GRKs) and β-arrestins is characterized as
inducing desensitization of G-protein mediated signal trans-
duction [98]; β-arrestin binding blocks G-protein mediated
signaling and facilitates receptor internalization. However,
emerging data suggest receptor activated β-arrestins can
stimulate signaling pathways independently of G-protein
activation [99]. Thus, β-arrestin signaling has physiologic
consequences distinct from G-protein coupled signaling
[99]. It is, therefore, of great interest to understand the
functional outcome of β-arrestin regulation of the GLP-1
receptor.Experimental Diabetes Research 5
In INS-1E insulinoma β-cells, siRNA knockdown of β-
arrestin-1 reduces GLP-1 induced insulin secretion [30].
These experiments implicate β-arrestin-1 in GLP-1 receptor
activity, but the mechanism responsible for the diminution
of GLP-1 action is not explicitly characterized. An alternate
explanation for lower GLP-1 stimulated insulin secretion
could be reduced tonic inhibition from anti-insulinotropic
Gαi-coupled GPCRs resulting from β-arrestin-1 removal.
Further, in this study, insulin secretion induced by glucose
alone is severely attenuated by β-arrestin-1 knockdown
making it diﬃcult to establish direct causality between
β-arrestin-1 knockdown and GLP-1 receptor dependent
signaling.
In studies using MIN6 insulinoma β-cells, GLP-1 recep-
tor stimulation is shown to induce a biphasic activation of
ERK [100]. This eﬀect is comprised of an initial cAMP-
dependent transient activation of ERK and a prolonged β-
arrestin-1 dependent activation of ERK [100]. β-arrestin-1
dependent ERK activity promotes Bad phosphorylation and
consequently mediates prosurvival eﬀects of GLP-1 receptor
agonists on high glucose induced apoptosis. Because many
biochemicalmechanismsinMIN6cellsareoperantinmouse
islets, this report elegantly delineates separable pathways for
GLP-1 receptor induced insulin secretion (Gαs-cAMP axis)
versus antiapoptotic signaling (β-arrestin-1 → p90RSK →
Bad axis). It should be noted, though, that this study also
contains experimental caveats; for example, the authors are
unable to cause glucotoxic apoptosis in primary islet cultures
and thus fail to validate the eﬃcacy of GLP-1 anti-apoptotic
signaling in their islet system.
In vivo analysisofinsulinsecretioninβ-arrestin-1knock-
out mice indicates glucose stimulated insulin secretion is
reduced by over 80% [30,100]. Accordingly, it is problematic
to ascribe any physiologic alterations to GLP-1 receptor
agonists in β-arrestin-1 knockout mice as being directly
due to the GLP-1 receptor, given that β-arrestins are likely
crucial signal regulatory proteins for hundreds of GPCRs.
This is exempliﬁed by the recent observation that β-arrestin-
2 knockout mice are insulin resistant [101]. A key point
to contextualize these studies is that although numerous
reports in rodents show positive eﬀects of GLP-1 or exendin-
4o np a n c r e a t i cβ-cell replication, β-cell mass, and function
in preclinical models [102, 103], less data are available
regarding GLP-1 agonist modulation of β-cell apoptosis
or neogenesis in humans (discussed in [104]). One report
does, however, demonstrate GLP-1 mediated attenuation of
apoptosis and enhanced insulin responsiveness in an ex vivo
human islet preparation [105]. Similarly, recent evidence
demonstrates that GLP-1 receptor agonism induces β-cell
replication in human islet grafts [106].
3. StructuralEvaluationof the GLP-1 Receptor
Understanding the molecular mechanisms whereby peptide
ligands induce GLP-1 receptor signaling should enhance
new eﬀorts to optimize small molecule activators of the
GLP-1 receptor. Various approaches are being explored that
may ultimately inform more rationale design strategies for
small molecule GLP-1 receptor agonists. A comprehensive
review of currently disclosed low molecular weight GLP-1
receptor activators is presented in this issue of Experimental
Diabetes Research; see Willard et al. for review. Importantly,
new strategies to exploit potential small molecule binding
to the GLP-1 receptor are advancing as a result of progress
in GPCR molecular and structural biology. Extensive site-
directed mutagenesis studies have been carried out on the
G L P - 1r e c e p t o ra sh a v es t r u c t u r ea c t i v i t ys t u d i e so np e p t i d e
GLP-1 ligands. It is beyond the scope of this review to cover
these studies, however, we recognize that such eﬀorts have
been a valuable starting point in eﬀorts to understand GLP-1
receptor biochemistry [107, 108].
3.1. Intramolecular Endogenous Peptide Agonists. Dong and
colleagues proposed a novel activation mechanism for class
B1 GPCRs [109] whereby peptide ligand interaction with
the receptor induces a conformational change that exposes
an intramolecular “endogenous agonist” epitope within
the ECD of a GPCR. The “endogenous agonist” motif is
proposed to act at the transmembrane domains to facilitate
receptor activation. This hypothesis is largely derived from
mutagenesis, peptide cross-linking, and molecular modeling
studies using the secretin receptor [109]. In support of the
concept, synthetic peptides derived from the ECD of the
secretin receptor are shown to be low potency, high eﬃcacy
agonists of the secretin receptor. The minimized pharmaco-
phore for the secretin receptor is a tri-peptide Trp70-Asp71-
Asn72 [109].TranslationofthisﬁndingtotheGLP-1receptor
identiﬁed an analogous peptide, Asn63-Arg64-Thr65-Phe66-
Asp67 (NRTFD), as a low potency but fully eﬃcacious GLP-
1 receptor agonist [110]. Although these short peptides
have low aﬃnity and poor receptor selectivity, making them
unlikely starting points for lead optimization and drug
development, the molecules identify a potential binding site
f o rc o m p o u n da c t i o no nt h eG L P - 1r e c e p t o r .S t r u c t u r a l
elucidation of these features should be enlightening. The
GLP-1 receptor “endogenous agonist” peptide maps to the
β1 strand of the GLP-1 receptor ECD crystal structure [74].
However, analyses of these structural data suggest Asn63 is
solvent exposed, but the majority of the peptide is not; these
results make it diﬃcult at this point to clearly understand
the molecular mechanism proposed for the “endogenous
agonist” peptides without further information around the
structure or dynamics of the GLP-1 receptor. A subsequent
report used an elegant cross-linking approach coupled with
radiochromatography (see Section 3.3) to identify the site
of action of the NRFTD peptide as being extracellular loop
3 in close proximity to transmembrane domain 6 [111].
The mechanism of action of the NRFTD peptide may be
analogous to that of the “pepducins” [112]. Pepducins are
short peptides derived from the intracellular loops of GPCRs
that act allosterically to modulate receptor signaling [113].
3.2. Crystal Structure of the GLP-1 Receptor ECD. Receptor
binding and functional studies show both GLP-1 (Kd =
0.3nM) and exendin-4 (Kd = 0.1nM) bind with high
aﬃnity and are full agonists at the GLP-1 receptor [26,6 Experimental Diabetes Research
57]. In addition, competition binding studies suggest these
peptides use the same ligand binding site within the receptor
[114]. However, in experiments exploring the initial ligand-
receptor binding event, data show exendin-4 binds the
isolated soluble form of the GLP-1 receptor ECD with
much greater aﬃnity (13nM) compared to GLP-1 (800nM)
[114, 115]. It was hypothesized that this phenomenon occurs
because exendin-4 contains nine additional amino acids at
its C-terminus that enable further binding contacts with the
ECD [77, 115]. Importantly, the crystal structures of the
ECD in complex with either bound GLP-1 or exendin-4(9-39)
show these peptides share a very similar mode of binding,
and there is no interaction between the last seven residues
of the nine amino acid C-terminal extension of exendin-4
with the ECD [74, 75]( Figure 3). Alternatively, biophysical
studies suggest the higher propensity of exendin-4 to form
helical conformations in solution compared to GLP-1 results
in its enhanced binding aﬃnity [73, 114]. However, this area
is still in need of further exploration because other reports
using a membrane-tethered form of the ECD demonstrate
GLP-1 (IC50 = 160nM) and exendin-4 (IC50 = 20nM)
bind the receptor with closer aﬃnity [116]. Recent studies
highlight this incongruity as exendin-4 (Kd = 0.9μM) and
GLP-1 (Kd = 1μM) have equivalent aﬃnities for the ECD,
as measured by surface plasmon resonance [117]. While
studies using puriﬁed forms of the ECD are informative,
these latter results may highlight the relatively artiﬁcial
nature of approaches using the soluble form of the ECD.
Therefore, experimental methodologies allowing structural
characterization of the full length, intact GLP-1 receptor are
needed.
3.3. GLP-1 Receptor Photoaﬃnity Labeling. In the absence of
a high resolution crystal structure of the full length GLP-1
receptor, photoaﬃnity labeling has been used as an alternate
approach to identify potentially important ligand-receptor
interactions. An inherent advantage of this technique is that
whole cells expressing the native receptor or membrane
preparations enriched with a receptor of interest are used so
the receptor is folded and presented in its proper structural
orientation [118–120]. These studies typically use a radio-
labeled version of the natural ligand engineered to contain
ap h o t o r e a c t i v em o i e t ys u c ha sp-benzoyl-l-phenylalanine
(Bpa). Ultraviolet photolysis of a probe in complex with its
receptor covalently labels residues of the receptor that are
in close spatial approximations with important structural
regions of the ligand. The labeled amino acids within
the targeted receptor can then be identiﬁed using manual
cycles of Edman degradation sequencing of isolated receptor
fragments [121]. For the GLP-1 receptor, this technique has
established spatial approximations between several ligand-
receptor residues that likely occur in the “agonist occupied”
receptor conformation. In studies intended to further assess
the initial binding event, C-terminal residues, Ala24 and
Gly35, of GLP-1 are shown to dock in close proximity near
Glu133 and Glu125 of the ECD, respectively [122]. These
data are in line with the 2.1 ˚ A resolution crystal structure
of the ECD-GLP-1 complex showing GLP-1 binding occurs
v i aac o n t i n u o u sC - t e r m i n a lα-helix formed by the sequence
spanning Thr13 and Val33 with residues between Ala24 and
Val33 directly interacting with the ECD [74]. Overall, these
data are consistent with the initial binding event proposed
by the “two-step” model. Somewhat surprisingly, results
from studies testing GLP-1 probes with Bpa incorporated at
positions 12 and 16 show docking of this region also near
residues contained within the ECD. These data predict Phe12
and Val16 are positioned near Tyr145 and Leu141,r e s p e c t i v e l y ,
of the ECD, sites located in the distal region of the ECD
immediately upstream of the ﬁrst transmembrane segment
of the receptor [123, 124].
Importantly, photoaﬃnitycross-linking studieshavealso
establishedpotentialcontactsbetweentheextracellularloops
of the receptor with residues of GLP-1. This work is helping
provide better insights into the orientation of the ligand
bound N-terminal region of GLP-1 with the receptor core.
For studies aimed at identifying structural elements involved
with the “second step” of GLP-1 binding and receptor
activation, an N-terminus labeled photo-labile GLP-1 probe
was generated. Because changes to the N-terminal His7 are
not well tolerated [125] ,ap r o b ew i t hB p aN - t e r m i n a l l y
attached to His7 (at a new position 6) was used to better
understand spatial approximations between the most N-
terminalresiduesofGLP-1andthereceptor.Thesedatashow
the N-terminus positions near Tyr205 in the ﬁrst extracellular
loop of the receptor [123]. Similarly, using a mid-region
position20probe,Trp297 withinthesecondextracellularloop
of the receptor positions within close proximity to Leu20
of GLP-1 [124]. Taken together, X-ray structural data of
the ECD in complex with the C-terminus of GLP-1 and
the cumulative results from photoaﬃnity labeling studies
provide experimentally derived information with which to
generate a more accurate molecular model of the ligand
binding pocket for the GLP-1 receptor [124].
3.4. Emerging Biochemical Technologies. Although progress
is continuing, integrated strategies pairing classic receptor
pharmacology with newer biophysical and structural biology
techniques are needed to progressively reﬁne a model
for GLP-1 receptor activation. New techniques aimed at
understanding ligand dependent conformational changes in
the GLP-1 receptor should aide small molecule discovery
pursuits. One emerging approach is the application of
solution phase peptide amide hydrogen/deuterium exchange
(HDX) coupled with mass spectrometry (MS) for the study
of GPCRs. In contrast to photoaﬃnity labeling, HDX-
MS does not require generating probes that require in-
corporation of a bulky moiety, such as the hydrophobic
Bpa, and must retain the binding and activation properties
of the natural ligand. Alternatively, HDX-MS is based on
the principle that for proteins in solution, amide bond
hydrogen atoms are exchangeable, and diﬀerences in the
rate of exchange are indicative of local accessibility and
thus can reﬂect the conformational status of a protein [126,
127]. Deuterium incorporation into the peptide backbone
increases protein mass, and upon protease cleavage, the
location and degree of hydrogen/deuterium exchange can beExperimental Diabetes Research 7
mapped via MS analysis. Although technically diﬃcult to
apply to membrane proteins, methods have advanced that
better enable puriﬁcation procedures for isolating GPCRs
using detergents that help maintain native structure, protein
solubility, and functional activity. From these advances,
HDX-MS has now been used to study ligand induced con-
formational changes of the β2 adrenergic receptor [128,
129]. These biochemical studies demonstrate that distinct
receptor conformations are elicited by ligands with diﬀerent
intrinsic eﬃcacies. Further, an elegant parallel MS approach
has utilized covalent derivatization of cysteine and lysine
residues with stable isotope labeled reactive functional-
ities to assess dynamic conformational changes elicited
by β2 adrenergic receptor ligands [130]. These studies
highlight the diversity of receptor conformations induced
by ligands with apparently similar functional capacities.
Together, this work provides further experimental evidence
for the existence of multiple ligand speciﬁc conformations of
GPCRs.
3.5. Recent Advances in GPCR Crystallography. The ﬁrst
GPCR crystal structure determined was that of Rhodopsin in
2000 [131]. While informative about the general principles
of GPCR structure, and having utility as a homology
model template for closely related class A GPCRs, this
information has not signiﬁcantly impacted drug discovery
activities for class B1 GPCRs. However, recent advances
in GPCR biochemistry and macromolecular crystallography
have accelerated the pace of structure determination for
this important target class [132]. Since 2007, multiple new
class A GPCR structures have been determined, including
adrenergic,adenosine,chemokine,dopamine,andhistamine
receptors [132]. In many cases, structures of multiple
ligands with cognate GPCRs are solved. Moreover, the
recent determination of a G-protein bound complex of
an activated GPCR represents a landmark achievement
of GPCR crystallography [133]. Several new technological
advances have been developed to facilitate these pursuits,
including novel detergents [134], creative receptor-fusion
proteins [135], camelid nanobodies [136], and lipidic cubic
phase crystallization [137]. Consequently, we anticipate that
signiﬁcant eﬀort may now turn toward determining the
crystal structures of class B1 GPCRs.
4. Conclusions
It is clear the GLP-1/GLP-1 receptor axis is a key physiologic
regulator of glucose metabolism, and diabetic patients
treated with degradation resistant GLP-1 receptor peptide
agonists, exenatide and liraglutide, experience improved
glucose homeostasis. Therefore, eﬀorts to identify orally
active small molecule GLP-1 receptor agonists are justiﬁably
being pursued. While several scaﬀolds are now reported (see
Willard et al. in this issue of Experimental Diabetes Research),
high-throughput screening campaigns and other discovery
approaches have largely failed to identify quality chemical
starting points that have been successfully optimized into
therapeutic agents. The lack of apparent success is likely
due to the inherent diﬃculty of lower molecular weight,
nonpeptide molecules to mimic the complex nature of
peptide ligand binding to the GLP-1 receptor ECD and
transmembraneregionsneededtoinduceintrinsicstructural
changes in the receptor to elicit signal transduction.
Fortunately, the availability of peptide ligands for the
GLP-1 receptor enables very detailed assessment of GLP-
1 receptor signaling pathways, and newer biophysical tech-
niques are helping interrogate the integral mechanisms
involved in receptor activation. Further, advances in struc-
tural biology methodologies for GPCRs are now rapidly
occurring, and application of these techniques to class B1
GPCRs will be groundbreaking. Assimilation of structural
information for the full length, intact GLP-1 receptor and
improved assay systems with which to monitor the GLP-
1r e c e p t o ri nd i ﬀerent conformational states will likely be
critical to advancing nascent eﬀorts to identify GLP-1 recep-
tor small molecule ligands. Once novel compounds emerge,
it will be important to optimize molecules using testing
schemes that incorporate signal transduction mechanisms
of GLP-1 physiology, especially GLP-1 receptor stimulation
of cAMP production to enhance glucose dependent insulin
secretion.
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